These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16401594)

  • 1. Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.
    El-Kamel A; Al-Dosari H; Al-Jenoobi F
    Drug Deliv; 2006; 13(1):55-9. PubMed ID: 16401594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of the ocular bioavailability of carteolol by ion pair.
    Higashiyama M; Tajika T; Inada K; Ohtori A
    J Ocul Pharmacol Ther; 2006 Oct; 22(5):333-9. PubMed ID: 17076627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new long acting ophthalmic formulation of carteolol containing alginic acid.
    Séchoy O; Tissié G; Sébastian C; Maurin F; Driot JY; Trinquand C
    Int J Pharm; 2000 Oct; 207(1-2):109-16. PubMed ID: 11036236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate.
    El-Kamel AH
    Int J Pharm; 2002 Jul; 241(1):47-55. PubMed ID: 12086720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity.
    Ishii Y; Nakamura K; Matsuki S; Uemura N; Muraguchi R; Nakagawa M; Nakano S; Nakatsuka K
    J Clin Pharmacol; 2002 Sep; 42(9):1020-6. PubMed ID: 12211218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit.
    Tissié G; Sébastian C; Elena PP; Driot JY; Trinquand C
    J Ocul Pharmacol Ther; 2002 Feb; 18(1):65-73. PubMed ID: 11858616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement in Corneal Permeability of Dissolved Carteolol by Its Combination with Magnesium Hydroxide Nanoparticles.
    Nagai N; Yamaoka S; Fukuoka Y; Ishii M; Otake H; Kanai K; Okamoto N; Shimomura Y
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients.
    Renard P; Kovalski JL; Cochereau I; Jaulerry S; Williamson W; Elena PP; Lablache Combier M; Allaire C; Siou-Mermet R
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1221-7. PubMed ID: 16003515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin.
    Qi H; Chen W; Huang C; Li L; Chen C; Li W; Wu C
    Int J Pharm; 2007 Jun; 337(1-2):178-87. PubMed ID: 17254725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation of carteolol chitosomes for ocular delivery: formulation optimization,
    Zafar A; Alruwaili NK; Imam SS; Alsaidan OA; Alharbi KS; Yasir M; Elmowafy M; Ansari MJ; Salahuddin M; Alshehri S
    Cutan Ocul Toxicol; 2021 Dec; 40(4):338-349. PubMed ID: 34340615
    [No Abstract]   [Full Text] [Related]  

  • 11. Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery.
    Marchal-Heussler L; Sirbat D; Hoffman M; Maincent P
    Pharm Res; 1993 Mar; 10(3):386-90. PubMed ID: 8464811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits.
    Tayel SA; El-Nabarawi MA; Tadros MI; Abd-Elsalam WH
    Int J Pharm; 2013 Feb; 443(1-2):293-305. PubMed ID: 23333217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of topical beta-adrenergic antagonists in rabbit aqueous humor evaluated with the microdialysis method.
    Ohtori R; Sato H; Fukuda S; Ueda T; Koide R; Kanda Y; Kiuchi Y; Oguchi K
    Exp Eye Res; 1998 Apr; 66(4):487-94. PubMed ID: 9593641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration].
    Kawase K; Yamamoto T; Muramatsu T; Ono J; Nakajima T; Matsuhisa A; Sugiura T; Migita M; Ishikawa Y
    Nippon Ganka Gakkai Zasshi; 2010 Nov; 114(11):976-82. PubMed ID: 21141077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
    Yamamoto T;
    Nippon Ganka Gakkai Zasshi; 2007 Jun; 111(6):463-72. PubMed ID: 17601060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-situ ocular absorption of ophthalmic beta-blockers through ocular membranes in albino rabbits.
    Sasaki H; Ichikawa M; Kawakami S; Yamamura K; Mukai T; Nishida K; Nakamura J
    J Pharm Pharmacol; 1997 Feb; 49(2):140-4. PubMed ID: 9055184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long acting ophthalmic gel formulations of atenolol.
    Hassan MA
    Drug Dev Ind Pharm; 2007 Nov; 33(11):1192-8. PubMed ID: 18058315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery.
    Liu Y; Liu J; Zhang X; Zhang R; Huang Y; Wu C
    AAPS PharmSciTech; 2010 Jun; 11(2):610-20. PubMed ID: 20354916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebral penetration of carteolol hydrochloride in rats.
    Kudo S; Umehara K; Abe Y; Furukawa M; Odomi M
    Psychopharmacology (Berl); 1997 Jun; 131(4):388-93. PubMed ID: 9226741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case.
    Battistini FD; Tártara LI; Boiero C; Guzmán ML; Luciani-Giaccobbe LC; Palma SD; Allemandi DA; Manzo RH; Olivera ME
    Eur J Pharm Sci; 2017 Jul; 105():188-194. PubMed ID: 28506871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.